Health
It is a prime political aim and social necessity to increase the overall health of the population and ensure that it receives equitable health care, a concern challenged by several factors: demographic change, costly new technologies and drugs and health care systems’ troubled financial situations.
Challenges:
+ Identifying effective drugs and health services with high benefits and a good safety profile (i.e. low risks)
+ Increasing costs due to an aging population and technological advancement
+ High demands and expectations from society
+The pressure for innovation
We offer:
+ Benefit-risk assessments of drugs using Multi-Criteria Decision Analysis (MCDA) and Decision Conferencing – both before, during and after approval (marketing authorisation)
- identifying benefits and risks,
- engaging key experts via Decision Conferencing
+ An integrated socio-technical approach to the prioritisation and strategic budgeting of health services (commissioning):
- identifying benefit-cost-ratios (value for money analysis),
- engaging key stakeholders via Decision Conferencing (commissioners, providers, doctors, patient representatives, health care experts, local community representatives, etc.)
Selection of Reference Projects:
+ Benefit-risk assessments of drugs based on Multi Criteria Decision Analysis (MCDA) and Decision Conferencing in the context of approval processes of the European Medicines Agency (EMA) for international pharmaceutical companies
+ Socio-technical strategic budgeting of health care services (commissioning) for the United Kingdom’s National Health Service. This involved a series of stakeholder workshops and a decision conference and integrating the results into a five-year strategy plan designed to guide the work of a primary care trust (PCT).
Contact
Cornelius Schaub
c.schaub@@decisioninstitute.eu